logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
N

Neeltje Steeghs

Netherlands Cancer Institute
H指数:48
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors

塞格图单抗阿穆纳鲁金的安全性与药代动力学、药效学及抗肿瘤活性：一项针对晚期和/或转移性实体瘤患者的I期研究

ESMO Open
IF8.3
2026-05-130
OAAI
U. Lassen; E.M.J. van Brummelen; I. Melero; E. Angevin; H. Joensuu; N.H. Segal; M. Mau-Sørensen; N. Steeghs; M.E. Rodríguez-Ruiz; K. Homicsko; J. Tabernero; M. Cañamero; D. Dejardin; C. Habigt; E. Rossmann; E. Guarin; G. Babitzki; H.E.S. Baumann; A.P. Silva; C. Adessi
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study

肿瘤局部CD40激动与MP0317，一种FAP x CD40 DARPin，重新编程晚期实体瘤患者的肿瘤微环境: 一项开放标签，非随机，剂量递增的1期研究

Nature Cancer
IF28.5
2026-05-010
OAAI
Neeltje Steeghs; Carlos Gomez-Roca; Iphigénie Korakis; Eelke Gort; Hilde De Winter; Nina Stojcheva; Vaia Stavropoulou; Jennifer Krieg; Paul Baverel; Elena Fernandez; Ana Maria Florescu; Lea Hoenig; Michael Peter Sanderson; Vladimir Kirkin; Philippe Legenne; Philippe Alexandre Cassier
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

阿特珠单抗联合贝伐珠单抗在MSI-like转移性结直肠癌中的有效性和安全性：一项多中心、单臂、II期、开放标签临床试验

ESMO Open
IF8.3
2025-12-020
OAAI
E. Elez; S. Siena; A. Sartore-Bianchi; J. Ros; F. Ciardello; E. Martinelli; N. Steeghs; S. Huijberts; A. Cervantes; S. Roselló; S. Tejpar; B. Wilmsen; R. Salazar; C. Santos; G. de Schaetzen; S. Muñoz; R. Bernards; V. Moreno; E. García-Galera; R. Alemany
Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof-of-Concept Study with Alectinib

使用稳定同位素标记的微示踪剂减轻癌症患者药物相互作用研究负担：一项关于Alectinib的可行性研究

CLINICAL PHARMACOLOGY & THERAPEUTICS
IF5.5
2025-11-010
OAAI
Mohmaed Ali, Ma Ida; van der Heijden, Lisa T.; Tibben, Matthijs; Rosing, Hilde; Kalicharan, Raween; Ruiter, Gerrina; Beijnen, Jos H.; Huisman-siebinga, Hinke; Huitema, Alwin D. R.; Steeghs, Neeltje
Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer

II期研究评估elraglusib（9-ING-41），一种GSK-3β抑制剂，与吉西他滨联合nab-紫杉醇用于既往未治疗的转移性胰腺癌。

ESMO Open
IF8.3
2025-06-010
OA
D. Mahalingam; A. Saeed; S.F. Powell; M. Huerta; V. Sahai; A.L. Coveler; E.J. Davis; N. Steeghs; M. Mulcahy; A.G. Raufi; L. Cavalcante; A. Cervantes; J. Berlin; T. Weisskittel; A. Ugolkov; A.P. Mazar; W. Mikrut; S. Smith; F.J. Giles; B.A. Carneiro
An ultra-sensitive liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 2H6-alectinib and alectinib in human plasma to support a microtracer food-effect trial

一种超灵敏的液相色谱串联质谱法，用于同时定量测定人血浆中的2H6-alectinib和alectinib，以支持微追踪剂食物效应试验

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
IF2.8
2025-03-010
PRE
van der Heijden, L. T.; Tibben, M. M.; Ali, M. I. Mohmaed; Aardenburg, L. G. J.; Steeghs, N.; Beijnen, J. H.; Rosing, H.; Huitema, A. D. R.
Double burden: financial toxicity in patients with advanced soft tissue sarcoma at the start of first-line palliative chemotherapy: baseline data from the HOLISTIC study

双重负担：接受一线姑息化疗的晚期软组织肉瘤患者的财务毒性：HOLISTIC研究基线数据

SUPPORTIVE CARE IN CANCER
IF3
2025-02-270
OA
Roets, E.; Younger, E.; Jones, R. L.; Hollander, D. den; Desar, I. M. E.; Young, R. J.; Oosten, A. W.; de Haan, J. J.; Gelderblom, H.; Steeghs, N.; van der Graaf, W. T. A.; Husson, O.

研究方向

暂未获取到该数据
A
Alwin D. R. Huitema
H 指数:67论文数:733被引数:1.8万
H
Hans Gelderblom
H 指数:107论文数:1,322被引数:5.3万
R
Ron H.J. Mathijssen
H 指数:76论文数:888被引数:2.0万
W
Winette T.A. van der Graaf
H 指数:89论文数:906被引数:3.2万
I
Ingrid M.E. Desar
H 指数:36论文数:291被引数:4,225
J
Jos H. Beijnen
H 指数:129论文数:1,778被引数:7.5万
M
Martijn P. Lolkema
H 指数:53论文数:501被引数:1.4万
S
Stefan Sleijfer
H 指数:80论文数:658被引数:2.8万
S
Stefanie L. Groenland
H 指数:17论文数:58被引数:1,001
A
Anna K.L. Reyners
H 指数:36论文数:242被引数:4,254